Search Results for: PULMONARY DELIVERY Pulmonary Delivery of
Articles
Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR December 18, 2020
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Noble & Aptar Pharma Connected Medical Device Solution for Disease Management Adherence & Onboarding Patients October 7, 2020
Noble and Aptar Pharma recently announced the launch of AdhereIT - a connected, intuitive, and user-friendly onboarding solution for the...Orgenesis Announces Agreement to Acquire Koligo Therapeutics September 29, 2020
Orgenesis Inc. and Koligo Therapeutics, Inc. recently announced the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion….
SPECIAL FEATURE - Injection Devices: Will COVID-19 Deliver Growth to the Market? September 1, 2020
Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services July 8, 2020
Lonza Pharma & Biotech recently announced the establishment of a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its Bend, OR, site…..
2020 Respiratory Drug Development eBook – Inhaled Medications for Treating Unconventional Respiratory Diseases June 30, 2020
This second annual Drug Development & Delivery Respiratory eBook focuses on a few companies that are taking inhalation devices to a new level in drug delivery.
Nemera & Noble Announce Collaboration to Support Patients Who Self-Administer Medication June 17, 2020
Nemera, world leader in design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries, recently announced a collaboration with Noble….
Vectura Signs License & Development Agreement With Aerami Therapeutics June 11, 2020
Vectura Group plc recently announced the signing of a global license and development agreement with Aerami Therapeutics Inc. for inhaled….
Proveris Scientific Announces Contract Test Services to Support Development of SARS-CoV-2 (COVID-19) Inhaled Drug Therapies & Vaccines May 6, 2020
Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, recently announced the availability of contract test services to support….
TFF Pharmaceuticals Announces R&D Collaboration for a Universal Influenza Vaccine April 15, 2020
TFF Pharmaceuticals, Inc. recently announced that it has entered into a research collaboration with the University of Georgia’s Center for Vaccines and Immunology (CVI), along with….
TFF Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial December 2, 2019
TFF Pharmaceuticals, Inc. recently announced the initiation of its Phase 1 clinical trial of Voriconazole Inhalation Powder, a next-generation, direct-to-lung,...Bellerophon Receives Orphan Drug Designation September 18, 2019
Bellerophon Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation to nitric oxide for the treatment of...CureVac Enters Exclusive Collaborative Research Agreement August 13, 2019
CureVac AG recently announced it has entered into a Collaborative Research Agreement with Yale University for discovery research into mRNA-based……
2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal June 26, 2019
This e-Book highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.
Bellerophon Announces Agreement With FDA on Regulatory Approval Pathway for INOpulse April 9, 2019
Bellerophon Therapeutics, Inc. recently announced it has reached agreement with the US FDA on the regulatory approval pathway for INOpulse...SMART DEVICES - Add-On Connectivity Facilitates New Generation of Smart Inhalers April 1, 2019
Contributor Cindy H. Dubin reviews how the addition of electronic and connectivity to inhalers may improve patient adherence and, consequently, treatment efficacy.
AIT Receives Milestone Payment From Commercialization Partner February 7, 2019
AIT Therapeutics, Inc. recently announced it has received a milestone payment of $3.15 million from its commercialization partner Circassia Pharmaceuticals...Cantabio Pharmaceuticals to Present Positive In Vivo Efficacy Results August 6, 2018
Cantabio Pharmaceuticals Inc. recently announced that Dr. Gergely Toth, Cantabio's CEO, will present results from the company's DJ-1 protein targeting...Bellerophon Reaches Agreement With FDA on Study Design of Phase 2b Trial June 6, 2018
Bellerophon Therapeutics, Inc. recently announced that, following the receipt of minutes from a recent meeting with the US FDA, the company has reached agreement with the FDA on all key aspects of its planned Phase 2b study of INOpulse for the treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD).
AIT Therapeutics Presented Data From Inhaled Nitric Oxide Study June 6, 2018
AIT Therapeutics, Inc. recently announced the results of its study titled Nitric Oxide Inhalations in CF Patients Infected with Mycobacterium Abscessus Complex: A Prospective, Open-Labeled Multi-Center Pilot Study at the 2018 American Thoracic Society (ATS) Conference in San Diego, CA.
